Mechanistically, targeting FTO can suppress the expression of immune checkpoint genes, especially LILRB4, in an m6A-dependent manner, substantially increasing AML cell sensitivity to T cell cytotoxicity and overcoming decitabine-induced immune evasion [75]. Here, FTO is linked to acute myeloid leukemia.